Robert L. Coleman MD

Obstetrics & Gynecology•The Woodlands, TX

Gynecologic Oncology

Chief Scientific Officer, US Oncology Research

10101 Woodloch Forest DrThe Woodlands, TX 77380
Phone+1 281-974-8961

Dr. Coleman is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Coleman's full profile Already have an account?

Education & Training

Creighton UniversityB.S., Mathematics, 1983
University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 1991 - 1993
McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 1987 - 1991
Creighton University School of MedicineClass of 1987

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2025 - 2027
TX State Medical License 1992 - 2027
IA State Medical License 1994 - 1999
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Giants of Cancer Care MJH Life Sciences, 2020
APGO CREOG Excellence in Teaching APGO CREOG, 2019
CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Chemotherapy and/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer
UNKNOWN
PHASE3
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Start of enrollment: 2006 Nov 01
TERMINATED
PHASE1
Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma Start of enrollment: 2006 Dec 19
TERMINATED
PHASE2

Publications & Presentations

PubMed

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industr...
Robert L Coleman, Isabelle Ray-Coquard, Thomas J Herzog, Antonio González-Martín, Brian Slomovitz
International Journal of Gynecological Cancer. 2026-08-01
Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving ...
Matthew A Powell, Sharad Ghamande, Lars C Hanker, Destin Black, Nicoline Raaschou-Jensen
International Journal of Gynecological Cancer. 2026-08-01
Efficacy translation between phase II and phase III trials in gynecologic oncology: a cross-phase meta-comparative analysis.
Gabriel Levin, Lucy Gilbert, Bradely J Monk, Reitan Ribeiro, Peter Scalia
International Journal of Gynecological Cancer. 2026-07-01

Journal Articles

Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial Cancer
Shannon N Westin, Lois M Ramondetta, Kathleen M Schmeler, Pamela T Soliman, Nicole D Fleming, Jennifer K Burzawa, Alpa M Nick, Andrea M Milbourne, Diane C Bodurka, Rob..., American Journal of Obstetrics and Gynecology
Demcizumab Combined with Paclitaxel for Platinum-Resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer: The SIERRA Open-Label Phase Ib Trial
Robert Coleman, MD, Gynecologic Oncology
Minimally Invasive Versus Abdominal Radical Hysterectomy for Cervical Cancer
Pedro T Ramirez, Robert L Coleman, Michael Frumovitz, The New England Journal of Medicine

Books/Book Chapters

60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center
Chapter: Ovarian Cancer
Coleman RL, Gershenson DMEditors: MA Rodriquez, RS Walters, TW Burke.Springer, New York, NY2013
Gynecologic Oncology
Chapter: Targeted Therapy and Immunotherapy
Coleman R, Sabbatini P2012
An Atlas of Gynecologic Oncology: Investigation and Surgery
J. Richard Smith, Giuseppe del Priore, Robert L. Coleman, John MonaghanInforma HealthcareEdition 3rd,2011

Abstracts/Posters

Randomized Phase II Study of Docetaxel Plus Vandetanib vs. Docetaxel Followed by Vandetanib in Patients with Persistent or Recurrent Epithelial Ovarian, Fallopian Tube...
Coleman RL, Moon J, Sood AK, Delmore JE, Bonebrake AJ, Anderson GL, Alberts DS, Markman M, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2012
A phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
B. M. Slomovitz, J. Brown, T. A. Johnston, D. Mura, C. Levenback, J. Wolf, K. R. Adler, K. H. Lu, R. L. Coleman, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011
Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer.
R. L. Coleman, L. R. Duska, P. T. Ramirez, S. C. Modesitt, K. M. Schmeler, R. Iyer, M. Garcia, A. Sood, 2011 ASCO Annual Meeting, Chicago, IL, 1/1/2011

Lectures

Exploratory analysis of the effect of maintenance rucaparib on postprogression outcomes in patients (pts) with platinum-sensitive recurrent ovarian carcinoma (OC) and ...
2019 ASCO Annual Meeting - 6/1/2019
Unraveling the Risks and Benefits of Antiangiogenic Therapy for Ovarian Cancer Patients
UPMC Cancer Center, Pittsburgh, PA, 2015; Hackensack University Medical Center, Hackensack, NJ, 2015 - 1/24/2015
Session I: Statistical Design, FDA Drug Approval Procedures; FDA
Salt Lake City, UT - 1/20/2015

Other

Ovarian Cancer Update: Conversations with Oncology Investigators (Faculty Interview)
Coleman RL, Research to Practice
Miami, FL - 1/1/2011
Ovarian Cancer: Answers to the 10 Most Important Questions
Coleman RL, Hosted by CancerNet Japan. Sponsored by GOTIC (Gynecologic Oncology Trial and Investigation Consorti
1/9/2010
Recurrent Ovarian Cancer: State of the State
Coleman RL, Living Medical Textbook from Projects in Knowledge CME Activity - Oncology Women's Cancers Edition,
Little Falls, NJ - 1/19/2009

Authored Content

SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 2023
Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020
Prospective Phase II Trial of Levonorgestrel Intrauterine Device: Non-Surgical Approach for Complex Atypical Hyperplasia and Early Endometrial CancerAugust 2020

Press Mentions

What Was 2025’s Biggest News in Ovarian Cancer?January 6th, 2026
Dramatic Spike in Molecular Testing for Endometrial Cancer Tells “Positive Story”December 5th, 2024
SORAYA Analysis Highlights Mirvetuximab Soravtansine’s Value in ClinicMarch 25th, 2023